Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2018 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Reports Second Quarter 2018 Financial and Operating Results

Increased focus on T cell lymphoma in lead program, TTI-621 Initiated dosing of TTI-622 (SIRPaFc IgG4) in phase 1a/1b clinical trial Recruited Dr. Yaping Shou as Chief Medical OfficerNegotiated...
June 19, 2018 18:30 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Announces “At-The-Market” Issuance Program and Filing of Prospectus Supplement

TORONTO, June 19, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL) (“Trillium” or the “Company”), a clinical stage immuno-oncology company developing innovative therapies...
June 15, 2018 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Completes Amendment to SIRPaFc License Agreement

TORONTO, June 15, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...
June 14, 2018 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Doses First Patient With TTI-622, Its Second Immune Checkpoint Inhibitor Targeting CD47

TORONTO, June 14, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...
June 07, 2018 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Appoints Yaping Shou, MD, PhD as Chief Medical Officer

TORONTO, June 07, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...
June 05, 2018 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders

TORONTO, June 05, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...
May 11, 2018 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Reports First Quarter 2018 Financial and Operating Results

Focusing TTI-621 clinical development on T-cell lymphomaTTI-621 received Orphan Drug Designation for the treatment of cutaneous T-cell lymphomaPreclinical data with TTI-622 (SIRPaFc IgG4) presented at...
April 18, 2018 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Reports TTI-622 Preclinical Data at the 2018 AACR Annual Meeting

TORONTO, April 18, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer,...
April 12, 2018 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics to Report Preclinical Data on TTI-621 and TTI-622 at the AACR Annual Meeting 2018

TORONTO, April 12, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer,...
April 10, 2018 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Provides Update on Its TTI-621 and TTI-622 Clinical Programs

Successful broad signal-seeking efforts identify T-cell lymphoma as an indication responsive to TTI-621 therapy.Focusing TTI-621 intravenous trial on separate cutaneous and peripheral T-cell lymphoma...